Adult cardiomyocytes have little regenerative capacity following injury, and damaged myocardium heals via fibroblast proliferation and scar formation, leading to cardiac remodeling and heart failure. We and other reported that functional cardiomyocytes can be directly generated from fibroblasts using several combinations of cardiac-specific defined factors. Mouse fibroblasts can be directly converted into cardiomyocyte-like cells by overexpression of cardiac-specific transcription factors, Gata4, Mef2c, and Tbx5 (GMT), GMT plus Hand2 (GHMT), or Mef2c, Myocd, and Tbx5 in vitro. More recently, we and others reported that human fibroblasts can be reprogrammed into differentiated cardiomyocyte-like cells by overexpressing GMT plus Myocd and Mesp1 or Gata4, Hand2, Tbx5, Myocd, miR-1, and miR-133. We found that miR-133 promoted cardiac reprogramming by directly suppressing Snai1, a master gene of fibroblasts, and silencing fibroblast signature. In vivo cardiac reprogramming by GMT or GHMT also converted endogenous CFs into cardiomyocytelike cells in situ, and improved cardiac function after acute myocardial infarction in mouse. These studies demonstrate that direct cardiac reprogramming technology may be a potential approach that could regenerate diseased hearts. The present article reviews the recent studies in cardiac reprogramming, and discusses the hopes and challenges of direct cardiac reprogramming towards regenerative therapy.
Introduction
Heart disease is a major cause of adult and childhood mortality worldwide. Because postnatal cardiomyocytes have little or no regenerative capacity after injury, damaged hearts heal by scar formation rather than by cardiac muscle regeneration, potentially leading to cardiac remodeling and ultimately resulting in heart failure. Although current medical therapies can support damaged hearts, we cannot repair damaged cardiac tissues. Heart transplantation is an effective therapy for heart failure, but this opportunity is dependent on the number of donor organ available. Thus, successful and efficient cardiac regenerative therapies are desirable. The adult heart is composed of cardiomyocytes and other cell types, including cardiac fibroblasts (CFs) 1) .
The CFs exist in cardiac tissue, up to 50% of all cells in the adult heart, and supply a supporting structure in the developing heart. However, once adult heart is injured, CFs proliferate and discharge extracellular matrix and growth factors, leading to scar formation and fibrosis [2] [3] [4] . Thus,
given the abundance of fibroblasts in the heart, the strategy which reprograms resident cardiac fibroblasts into functional cardiomyocytes in situ may regenertate injured hearts and improve cardiac function.
Recently, a new approach to generate specific cell types by using combinations of specific transcription factors has emerged 7) . Based on the knowledge of the transcriptional circuits that specify cardiac lineage and differentiation of cardiomyocytes during embryogenesis, different combinations of cardiac transcription factors have been inspected for their ability to activate cardiac program in CFs. We initially found that mouse fibroblasts can be directly converted into cardiomyocyte-like cells by overexpressing cardiac-specigic transcription factors, Gata4, Mef2c, and Tbx5(GMT) in the fibroblasts 7) . Following our report, other groups also succeeded in direct cardiac reprogramming from mouse fibroblasts by expressing cardiac transcription factorseither (a) GMT plus Hand2 (GHMT) or (b) Mef2c, Myocd, and Tbx5 (MMT)-or by using cardiac-enriched microRNAs (miRNAs) 5, 6, 8) . More recently, we and others reported that human fibroblasts can be reprogrammed into differentiated cardiomyocytes by using GMT plus Myocd and Mesp1 or Gata4, Hand2, Tbx5, Myocd, miR-1, and miR-133 [19] [20] [21] .
In vivo cardiac reprogramming by GMT or GHMT also reprogrammed endogenous CFs into cardiomyocytelike cells and improved cardiac function after myocardial infarction 8, 17, 18) . We developed a polycistronic vector of GMT to transduce the three factors equally and found this system superior to injection of the three separate vectors for in vivo reprogramming 9) . These studies together suggested that direct cardiac reprogramming technology may be a promising new therapeutic approach for regenerative medicine that could reduce fibrotic tissues and improve cardiac function in diseased hearts. Here, we review recent studies of direct cardiac reprogramming and discuss the hopes and challenges of using this new technology in regenerative medicine (Fig.1 ).
Direct Reprogramming of Mouse Cardiac Fibroblasts into Cardiomyocytes by Transcription Factors
The ability to convert one mature cell type into another by overexpressing a transcription factor was first reported in 1987 [10] [11] . Davis et al. 10) found that MyoD , which encodes a transcription factor crucial for skeletal muscle formation and differentiation, converted fibroblasts into skeletal muscle cells in culture. In contrast, Evans et al.
showed that a dominant muscle fate was not the case for heterokaryons of fibroblasts and cardiomyocytes, and thus the transdifferentiation of fibroblasts into cardiomyocytes .
Following our initial publication of direct cardiac reprogramming, several other groups also reported the same phenomenon. Song et al. 8) sought to investigate the optimal combination of the cardiac transcription factors to reprogramm adult TTFs into functional cardiomyocytes.
They also used αMHC-GFP reporter mouse, and screened .
Cardiac Reprogramming Using MicroRNAs
MicroRNAs ( 
Reprogramming Human Fibroblasts to Cardiomyocytes by Defined Factors
Toward clinical application, it would be necessary to translate the mouse system into human. Nam et al. 19 
Addition of MIR-133 Promotes Cardiac
Reprogramming by Targeting SNAI-1
As stated above, we and others reported direct cardiac 
Reprogramming Endogenous Cardiac Fibloblasts into Cardiomyocytes in vivo
We speculated the main cause of low cardiac reprogramming efficiency in vitro might be the lack of natural environment for cardiomyocytes in plastic dishes. In vivo environment might be better for cardiac differentiation than that in vitro . To test the possibility of direct cardiac reprogramming in vivo , we and others investigated whether the gene transfer of reprogramming factors into infarcted mouse hearts could convert resident CFs into cardiomyocytes in situ 9, 8, 17, 18) . Mice harboring various lineage markers for the non-myocyte population were subjected to left anterior descending (LAD) ligation, causing fibroblasts to proliferate to form a scar. Qian et al. 17) directly injected GMT retroviruses into mouse hearts after myocardial infarction (MI) and showed that approximately 35% of cardiomyocytes in the border/infarct zone were newly generated iCMs derived from resident CFs. Of these iCMs, 50% had well- .
Conclusions
Despite excitement and huge potential of direct reprogrammng technology, many important questions and issues remain (Table 1) . Recently, we demonstrated that Snai1 is a key molecular roadblock during cardiac reprogramming, but other moelucules important for cardiac reprogramming remain unclear. We speculate secreted proteins, electrical and mechanical stimulation, and cell-tocell contact may promote cardiac reprogramming, accoding to the co-culture experiments in human iCMs. The safety issue associated with viral delivery of reprogramming factors may be another concern for clinical applications.
As a major limitation in the previous studies is the use of potentially harmful genome-integrating retroviruses, future study investigating whether fibroblasts can be reprogrammed into functional iCMs without viral integration is critical. Non-integrating viral vectors expressing cardiac reprogramming factors, cardiogenic small molecules, and synthetic oligonucleotides might be attractive options in clinical applications. Moreover, all in vivo studies reported so far were performed in acute MI mouse models, and it remains to be determined whether in vivo reprogramming can be applied to the context of chronic heart failure.
Further studies are required to address these questions, and optimization of cardiac reprogramming in human fibroblasts and demonstration of the therapeutic efficacy and safety of this approach in larger animals will be needed to advance this technology.
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